Gastrointestinal Very common (10% or more): Gastrointestinal adverse reactions (up to 73%), nausea (up to 44%), vomiting (up to 36%), diarrhea (up to 30%), constipation (up to 24.2%), abdominal pain (up to 20%) Common (1% to 10%): Dyspepsia, abdominal distension, eructation, flatulence, gastroenteritis, gastroesophageal reflux disease, gastritis, viral gastroenteritis, increased amylase, increased lipase, dry mouth, severe gastrointestinal adverse reactions, delayed gastric emptying Uncommon (0.1% to 1%): Acute pancreatitis, appendicitis Frequency not reported : Hemorrhoids, hiccups Postmarketing reports : Ileus, intestinal obstruction, severe constipation, hiccups, acute pancreatitis, necrotizing pancreatitis In clinical trials in adults using the subcutaneous injection for weight reduction, 73% of treated patients reported gastrointestinal adverse reactions, including severe reactions (4.1%)
Dose reduction Dropping back one dose level and maintaining there is the most common approach
The Takeaway This sub-analysis confirms that semaglutides cardiac benefits happen quickly and build-up over time, with the eventual extra weight loss further intensifying them
Semaglutide and Nt-Probnp in Obesity-Related Hfpef: Insights from the step-Hfpef program
Choosing and Preparing the Injection Site Semaglutide is a subcutaneous injection, which means it is delivered into the fatty tissue just beneath the skin, rather than into a muscle or a vein
Egg yolks, meanwhile, are packed with key nutrients like vitamins B2, B12, and iodine